A number of biologics have been trialled, mostly in adults, to treat severe asthma with a type (T)2-high inflammatory response, including mAb directed against IgE (omalizumab), IL-5 (mepolizumab), IL-5 receptor alpha (benralizumab), IL-13 (lebrikizumab and tralokinumab) and the IL-4 receptor alpha chain (dupilumab) [33, 34]. This evidence concerns the gene IL5 and asthma.